Vaxart, Inc. announced that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably with the injectable quadrivalent influenza vaccine (QIV) in a Phase 2 challenge trial. The study was completed with support from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS). The Vaxart oral tablet vaccine reduced the influenza infection rate by 48% compared to 38% with injectable QIV. Specifically, only 37% of the Vaxart subjects developed influenza infection compared with 44% who received the injectable QIV and 71% who received placebo. In the analysis that was performed by BARDA, the results for both vaccines were statistically significant compared to placebo, with p values of 0.001 for the Vaxart vaccine and 0.009 for QIV, exhibiting a strong trend by the Vaxart vaccine toward greater efficacy than injectable QIV. The new Phase 2 results complement previously reported data demonstrating that the Vaxart oral tablet vaccine protected against influenza disease at least as well as injectable QIV and highlighting the favorable safety and tolerability profile of the Vaxart vaccine.